To the Editor:

We describe a patient with gout who developed serious multiple system organ failure after the self-administration of colchicine together with loxoprofen.

A 38-year-old male (height 175 cm, weight 75 kg) with no pre-existing diseases had been prescribed colchicine (1 tablet) together with loxoprofen (1 tablet) for gout attack by his family physician. Following the severest pain attack at his toe that he had ever experienced, he self-administered 30 tablets of colchicine (15 mg) together with ten loxoprofen tablets (600 mg) within a 6-h period. His pain subsided 3 h after the last intake of the tablets, but he presented to our medical center because of gastrointestinal symptoms including nausea, vomiting, diarrhea, and hematemesis.

The patient developed acute renal failure on the second hospital day, and on the third hospital day, he entered a delirious state, with thrombocytopenia, respiratory failure, and severe hypotension. Granulocyte colony stimulating factor (250 μg/day) was administered for his severe pancytopenia on hospital days 4--7. On hospital day 9, his urine output began to increase, and on hospital day 18, the patient had been successfully weaned from the mechanical ventilation. He was discharged from the hospital on hospital day 26. All of the blood and laboratory parameters on hospital day 25 were within the normal ranges, but alopecia, muscle weakness (MMT 4/5), disappeared ankle tendon reflex, reduced evoked potentials of peripheral nerves, including the median, ulnar, and tibial nerves, remained (Table [1](#Tab1){ref-type="table"}).Table 1Blood, serum, and coagulation data during the hospitalization of this patientBlood, serum, and coagulation dataNormal rangeDay 1Day 2Day 3Day 4Day 5Day 6Day 7Day 18Day 25White blood cells (/ml)4000--7000297001950060009004009003500114008400Hemoglobin (g/dl)14.0--18.017.616.114.411.09.87.97.38.68.7Hematocrit (%)40.0--52.051.747.842.531.727.322.620.524.825.7Platelets (/ml)15.0--40.026.711.02.72.31.51.32.010.228.1Prothrombin time (%)85--1203645768787939577Prothrombin time (INR)2.31.891.211.101.101.051.031.20Activated partial thrombin time (s)28--4056.470.352.047.938.741.740.637.6Fibrinogen (mg/dl)200--400374598799766822692586396Alkaline phosphokinase (U/l)104--338257927141323565481359327179229Aspartate amino transferase (U/l)5--403754053442101881771158029Alanine amino transferase (U/l)5--355249424477100794431Lactate dehydrogenase (U/l)50--4001225013630107404850208311158351290506Creatinine phosphokinase (U/l)20--190105815182871193792928338379936Blood urea nitrogen (mg/dl)8--20424133282530328029Creatinine (mg/dl)0.6--1.54.43.83.52.72.82.62.22.80.9C-reactive protein (mg/dl)−0.335.5153.8854.2526.8525.5119.0521.052.720.95

The first symptom of this patient was that of gastrointestinal tract, followed by the subsequent multiple organ failure, including the cardiovascular, renal, hepatic, respiratory, myeloproliferative, central and peripheral nervous systems, which sequentially developed as precisely described in Stapczynski et al.'s review \[[@CR1]\]. The severity of our patient's colchicine intoxication correlated well to the intake doses; i.e., an oral intake of \<0.5 mg/kg only exerts gastrointestinal tract symptoms, that from 0.5 to 0.8 mg/kg results in multiple organ failure, and an oral intake of \>0.8 mg/kg can be lethal \[[@CR2]\]. The total intake of colchicine in this patient was 15 mg (0.2 mg/kg), and he did not have any pre-existing diseases. The co-administration of macrolides promotes colchicine's toxicities \[[@CR3], [@CR4]\], but, to our knowledge, there has been only one report of colchicine toxicity in association with indomethacin \[[@CR5]\]. Colchicine, anti-inflammatory drugs (NSAIDs), and corticosteroids are commonly used to treat gout. It would appear that a possible interaction between colchicine and NSAIDs could cause a fatal complication.
